- Home
- FRMI vs GMAB Comparison
FRMI vs GMAB Comparison
Compare FRMI & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRMI
- GMAB
- Stock Information
- Founded
- FRMI 2025
- GMAB 1999
- Country
- FRMI United States
- GMAB Denmark
- Employees
- FRMI N/A
- GMAB N/A
- Industry
- FRMI Real Estate Investment Trusts
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- FRMI Real Estate
- GMAB Health Care
- Exchange
- FRMI Nasdaq
- GMAB Nasdaq
- Market Cap
- FRMI 17.0B
- GMAB 17.4B
- IPO Year
- FRMI 2025
- GMAB N/A
- Fundamental
- Price
- FRMI N/A
- GMAB $33.56
- Analyst Decision
- FRMI
- GMAB Strong Buy
- Analyst Count
- FRMI 0
- GMAB 7
- Target Price
- FRMI N/A
- GMAB $41.17
- AVG Volume (30 Days)
- FRMI 25.0M
- GMAB 2.0M
- Earning Date
- FRMI 01-01-0001
- GMAB 11-05-2025
- Dividend Yield
- FRMI N/A
- GMAB N/A
- EPS Growth
- FRMI N/A
- GMAB 77.72
- EPS
- FRMI N/A
- GMAB 21.62
- Revenue
- FRMI N/A
- GMAB $3,646,881,232.00
- Revenue This Year
- FRMI N/A
- GMAB $24.52
- Revenue Next Year
- FRMI N/A
- GMAB $15.53
- P/E Ratio
- FRMI N/A
- GMAB $14.83
- Revenue Growth
- FRMI N/A
- GMAB 32.97
- 52 Week Low
- FRMI $24.50
- GMAB $17.24
- 52 Week High
- FRMI $36.99
- GMAB $33.61
- Technical
- Relative Strength Index (RSI)
- FRMI N/A
- GMAB 85.95
- Support Level
- FRMI N/A
- GMAB $28.36
- Resistance Level
- FRMI N/A
- GMAB $29.52
- Average True Range (ATR)
- FRMI 0.00
- GMAB 0.57
- MACD
- FRMI 0.00
- GMAB 0.31
- Stochastic Oscillator
- FRMI 0.00
- GMAB 99.13
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.